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OBJECTIVES To evaluate the long-term outcome of patients randomized to coronary bypass surgery or
coronary angioplasty.
BACKGROUND The Emory Angioplasty versus Surgery Trial (EAST) is a single center randomized
comparison of a strategy of initial coronary angioplasty (n 5 198) or coronary bypass surgery
(n 5 194) for patients with multivessel coronary artery disease. The primary end point (death,
myocardial infarction or a large ischemic defect at 3 years) was not different, and repeat
revascularization was significantly greater in the angioplasty group. Subsequently, the
National Heart, Lung and Blood Institute supported a five-year extension of the trial.
METHODS After the three year anniversary visit, annual questionnaires, telephone contact and exami-
nation of medical records were accomplished until death or the eight year anniversary in 100%
of the patients surviving at 3 years.
RESULTS Survival at 8 years is 79.3% in the angioplasty group and 82.7% in the surgical group (p 5
0.40). Patients with proximal left anterior descending stenosis and those with diabetes tended
to have better late survival with surgical intervention although not reaching statistical
significance. After the first 3 years, repeat interventions remained relatively equal for both
treatment groups.
CONCLUSIONS Long-term survival is not significantly different between angioplasty and surgery, and late
(three to eight year) revascularization procedures were infrequent. Patients without treated
diabetes had similar survival in both groups. (J Am Coll Cardiol 2000;35:1116–21) © 2000
by the American College of Cardiology
The Emory Angioplasty versus Surgery Trial (EAST) was
the first trial supported by the National Heart, Lung and
Blood Institute (NHLBI) to compare the outcomes of the
strategy of performing angioplasty (n 5 198) or surgery
(n 5 194) in patients with multivessel coronary artery
disease (CAD) (1). Enrollment began in June 1987 and
ended in April 1990. Baseline characteristics reflected mul-
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tivessel patients who could undergo either procedure (Table
1). The primary end point was the composite of death, Q
wave myocardial infarction (MI) occurring over a three-year
follow-up or a major ischemic thallium defect at the
three-year follow-up visit. Secondary end points included
the components of the composite end point, the require-
ment for repeat interventional procedures and the economic
and quality of life impact. Angiographic evaluation was also
performed at one year and three years to assess the degree of
revascularization (2).
The three-year primary end point was reached by 27.3%
of the surgery patients and 28.8% of the angioplasty patients
(3). Death, which occurred in 6.2% of the surgery group and
7.1% of the angioplasty group, was also not different.
Several other studies evaluating the outcomes of surgery or
angioplasty also showed no significant differences in survival
(4–8). The major difference in all these studies, including
EAST, was the marked excess utilization of repeat revascu-
larization procedures in the angioplasty groups.
Because long-term follow-up may show further differ-
ences based on treatment selection, an extended five-year
follow-up was proposed and subsequently supported by the
NHLBI. Although the extended observations were not
designed to evaluate the original composite end point, and
the power was not adequate to evaluate mortality differ-
ences, it was important to track this population carefully to
understand possible trends that could strengthen larger
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long-term randomized trials. This report constitutes the
completed eight-year follow-up of all patients randomized
in EAST.
METHODS
The Emory Angioplasty versus Surgery Trial, a single center
study, was composed of patients referred for revasculariza-
tion at Emory University Hospital, Crawford W. Long
Hospital and the Atlanta VA Hospital. Eligibility require-
ments were patients of any age with multivessel CAD who
had not undergone prior angioplasty or surgery. Excluded
were those patients with left main disease, multiple chronic
total occlusions, old chronic occlusions (more than eight
weeks duration) of bypassable vessels serving viable myocar-
dium and an ejection fraction of 25% or less. Additionally,
patients judged to have insignificant myocardium at risk to
warrant surgery, those with MI within five days, and those
with other illnesses threatening survival were excluded.
Finally, patients judged to be unsafe for performance of
surgery by the surgical consultant or judged to be unsafe for
angioplasty by the angioplasty operator were excluded.
Of 842 patients eligible for the trial, 392 (198 assigned to
angioplasty and 194 to surgery) volunteered to be random-
ized. Randomization was performed separately for the
patients with two-vessel disease and those with three-vessel
disease. Follow-up was performed every six months for
three years, and a stress thallium study and coronary
arteriogram were performed at one year and three years.
After three years, follow-up of vital status, subsequent
hospitalizations and procedures was performed annually
from year 4 through year 8 by telephone contact with the
patient or family members. When hospitalizations were
identified, the hospital records were requested.
The primary focus of the extended follow-up is all-cause
mortality and requirement for repeat revascularization pro-
cedures. Death was also classified as to cause, and these were
divided into cardiac and noncardiac according to the pre-
defined classification scheme (1). Because routine electro-
cardiograms were not performed at Emory University after
the three-year follow-up visit and adjudication of Q wave
development was not performed after that point, no accu-
rate analysis of Q wave MI can be made over the extended
follow-up period.
Definitions. The angiographic definitions in EAST have
been previously reported (1,3). Two-vessel disease refers to
patients with obstruction in two of the three major coronary
systems; three-vessel disease refers to involvement of all
three systems. Proximal left anterior descending disease
refers to lesions in the proximal one third of that vessel. Left
ventricular ejection fraction was determined angiographi-
cally by the area length method. Diabetes mellitus was
reported for patients who were diagnosed and were on
therapy with insulin or oral hypoglycemic agents at the time
of randomization.
Statistical methods. Data were analyzed according to the
intention-to-treat principle. Unadjusted Kaplan-Meier sur-
vival curves are presented with p values calculated according
to the log-rank test (9). All tests are two-tailed, and a p
value #0.05 was considered to indicate statistical signifi-
cance. The study was not powered to detect a difference in
survival at three years. Taking the percutaneous translumi-
nal coronary angioplasty (PTCA) group as the reference
survival value (79.3%), one would require 7,192 patients to
detect an eight-year mortality absolute difference of 3%
between the groups (hazard ratio 0.84) with 90% power and
alpha 5 0.05, two-tailed (10). To detect a 5% difference
(hazard ratio 0.74) would require 2,466 patients. With the
available number of patients (n 5 392), one would have 78%
power to detect hazard ratio of 0.5 (absolute difference in
mortality of 9.8%).
Abbreviations and Acronyms
BARI 5 Bypass Angioplasty Revascularization
Investigation
CAD 5 coronary artery disease
EAST 5 Emory Angioplasty versus Surgery Trial
MI 5 myocardial infarction
NHLBI 5 National Heart, Lung and Blood Institute
PTCA 5 percutaneous transluminal coronary
angioplasty
Table 1. Baseline Demographic and Clinical Characteristics of
the Randomized Patients
CABG PTCA
Characteristic (n 5 194) (n 5 198)
Age (yr) 61.4 6 10.0 61.8 6 10.1
Male gender 141 (72.7) 148 (74.7)
White 183 (94.3) 184 (92.9)
No. of diseased vessels
Two 117 (60.3) 119 (60.1)
Three 77 (39.7) 79 (39.9)
Proximal LAD stenosis
$50%
143 (73.7) 140 (70.7)
Number of lesions per
patient
3.4 6 1.4 3.4 6 1.2
Ejection fraction (%) 62.0 6 11.8 60.8 6 11.6
Prior myocardial infarction 79 (40.7) 81 (40.9)
Congestive heart failure 8 (4.1) 5 (2.5)
Angina
CCS class III and IV 155 (7.9) 147 (74.2)
Diabetes mellitus 41 (21.2) 49 (24.7)
Hypertension 100 (51.5) 106 (53.5)
Total cholesterol (mg/dl) 224.1 6 46.7 218.0 6 46.5
Plus-minus values are means 6 SD; all other values are numbers of patients, with
percentages given in parentheses.
CCS 5 Canadian Cardiovascular Society; LAD 5 left anterior descending artery.
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RESULTS
Patients were followed between eight and 10.5 years. All
392 patients were followed until the eight-year anniversary
point or until death for a 100% follow-up rate. Although
there was almost identical survival at the three-year end
point (93.8% surgery vs. 92.9% angioplasty), there has been
a slight divergence of the survival curve since that time. At
eight years the surgery survival is 82.7% and the angioplasty
survival is 79.3%, and this does not reach statistical signif-
icance (p 5 0.40) (Fig. 1).
Because of the concern that patients with more diffuse
disease might have better outcomes with surgery, the
patients were randomized according to the presence of
three-vessel disease (40% of the patients) or two-vessel
disease (60% of the patients). At three years neither the
three-vessel disease patients nor the two-vessel disease
patients showed better survival by treatment assignment
(three-vessel: surgery 93.5%, angioplasty 91.1%; two-vessel:
surgery 94.0%, angioplasty 94.1%). By eight years there was
slight, but not significant, separation of the curves in favor
of surgery for three-vessel disease (three-vessel surgery
81.6%, angioplasty 75.5%, p 5 0.35) but not for two-vessel
disease (two-vessel surgery 83.4%, angioplasty 81.8%, p 5
0.75) (Fig. 2).
Patients with proximal left anterior descending stenosis
had little difference in survival at three years, and the curves
diverged slightly, but not significantly, for this cohort over
the remaining follow-up (eight-year surgical survival 85.6%,
angioplasty 79.6%, p 5 0.16) (Fig. 3).
Because diabetic patients in the Bypass Angioplasty
Revascularization Investigation (BARI) showed a signifi-
cant survival advantage in the surgery group, these patients
were also examined in EAST. There were 59 treated
diabetic patients in EAST (30 surgery, 29 angioplasty). At
three years the survival was similar (surgery 90%, angio-
plasty 93.1%), and this was also similar to the patients
without treated diabetes. In the extended follow-up this has
changed. After five years the curves began to diverge, and by
eight years, even though they did not reach statistical
significance, they favored surgery in this group (surgical
survival 75.5%, angioplasty 60.1%, p 5 0.23) (Fig. 4A).
Likewise, the angioplasty patients with diabetes had a worse
survival than the nondiabetic patients by eight years (non-
diabetic 82.6%, diabetic 60.1%, p 5 0.02) (Fig. 4B). Similar
to the BARI five-year follow-up of patients without treated
diabetes (11), this follow-up of EAST showed no survival
advantage for either treatment assignment for the 333
nondiabetic patients at eight years (surgery 84%, angioplasty
82.6%, p 5 0.71) (Fig. 4C).
Comparisons were made for all other baseline variables
including left ventricular function, age, gender, anginal
status, hypertension, cigarette smoking and baseline choles-
Figure 1. Survival of all EAST patients after initial treatment with
CABG or PTCA. The number of patients at risk and the
estimated probability of survival at 3, 5, 7 and 8 years are shown
below the figure. CABG 5 coronary artery bypass grafting;
EAST 5 Emory Angioplasty versus Surgery Trial; PTCA 5
percutaneous transluminal coronary angioplasty.
Figure 2. Survival of patients with three-vessel coronary disease
(Panel A) and patients with two-vessel coronary disease (Panel B).
The number of patients at risk and the estimated probability of
survival at 3, 5, 7 and 8 years are shown below the figure. CABG 5
coronary artery bypass grafting; PTCA 5 percutaneous translu-
minal coronary angioplasty.
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terol values, and no survival differences by treatment assign-
ment were seen. Freedom from cardiac death was not
different for the entire cohort (surgery 92.3%, angioplasty
90.7%) at eight years (Fig. 5A). Cardiac survival among the
patients with three-vessel disease was 94.7% in the surgery
group and 87.7% in the angioplasty group (p 5 0.17) (Fig.
5B), consistent with the all-cause mortality. Overall, ap-
proximately one half of the deaths in EAST were classified
as noncardiac.
Further revascularization. After the initial procedure, ad-
ditional revascularization procedures were performed much
more commonly in the angioplasty randomized patients.
The first additional procedure occurred primarily in the first
three years. During the extended follow-up, the curves
representing the percent of patients having additional an-
gioplasty or surgery remain parallel for the treatment as-
signment groups. The surgery patients had very few surgical
procedures in follow-up, and after three years the percent of
angioplasty patients having surgery was also relatively low.
At eight years 2.4% of the surgery patients had had a second
operation and 29.3% of the angioplasty patients had under-
gone surgery (p , 0.001) (Fig. 6A). The use of angioplasty
in the follow-up period also favored surgery patients, but
this was an early effect, and after three years the curves of the
percent of patients requiring angioplasty remained parallel
to eight years. An additional 11.3% of the surgery patients
had first angioplasty between years 3 and 8, and an addi-
tional 7.5% of the angioplasty patients had first subsequent
angioplasty between years 3 and 8 (Fig. 6B). The curves of
the percent of patients having either angioplasty or surgery
in follow-up also remained parallel after the three-year
mark. For the surgery group, the increase from year 3 to year
8 was 12.7%, while the percent of angioplasty patients
having their first subsequent revascularization procedure
increased during the same period by 8.6%. However, due to
the early excess of repeat revascularization in the angioplasty
group, by eight years 26.5% of the surgery patients had had
an additional procedure compared with 65.3% of the angio-
Figure 3. Survival of patients with proximal left anterior descend-
ing stenosis. The number of patients at risk and the estimated
probability of survival at 3, 5, 7 and 8 years are shown below the
figure. CABG 5 coronary artery bypass grafting; PTCA 5
percutaneous transluminal coronary angioplasty.
Figure 4. Survival of treated diabetic patients (Panel A), patients
with initial PTCA treatment (Panel B) and patients without
treated diabetes (Panel C). The number of patients at risk and the
estimated probability of survival at 3, 5, 7 and 8 years are shown
below the figure. CABG 5 coronary artery bypass grafting;
PTCA 5 percutaneous transluminal coronary angioplasty.
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plasty patients (p , 0.001) (Fig. 6C). Because of restenosis,
a second procedure is frequently contemplated. Of the
angioplasty randomized patients, 55.6% had either a single
index procedure (36.4%) or only one additional angioplasty
(19.2%).
Detailed cost analysis of EAST during the first three
years has been published previously (12). Repeat procedures,
however, may be a surrogate for late cost. After the initial
procedure, the total number of subsequent surgeries in the
surgical group was four and in the angioplasty group 59.
The total number of subsequent angioplasties was 72 in the
surgery group and 181 in the angioplasty group.
DISCUSSION
Previous reports from EAST and other studies have shown
similar survival for multivessel patients treated with angio-
plasty or surgery. This long-term follow-up provided addi-
tional insight into survival and the percent of patients who
subsequently require an additional revascularization proce-
dure. In this single center study, almost 50% of eligible
patients could be randomized, and 100% follow-up has been
Figure 5. Percent of patients free from cardiac death for all EAST
patients (Panel A) and for patients with three-vessel coronary
disease (Panel B). The number of patients at risk and the
estimated probability of freedom from cardiac death at 3, 5, 7 and
8 years are shown below the figure. CABG 5 coronary artery
bypass grafting; PTCA 5 percutaneous transluminal coronary
angioplasty.
Figure 6. Percent of all EAST patients with subsequent PTCA
(Panel A), with subsequent CABG (Panel B) and with subsequent
CABG or PTCA (Panel C) after the initial revascularization proce-
dure. The number of patients at risk and the estimated probability of
the first subsequent procedure at 3, 5, 7 and 8 years are shown below
the figure. CABG 5 coronary artery bypass grafting; PTCA 5
percutaneous transluminal coronary angioplasty.
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completed at eight years. The modest size of the study
prevented definitive conclusions regarding survival differ-
ences, but the trends may be predictive of larger observa-
tions. The survival differences at five years closely approxi-
mate those found in BARI for the entire cohort and for
those without diabetes. Although no difference in the
diabetic population was seen at three years, the eight-year
follow-up was in the direction of the better late survival in
the surgery group as seen in BARI.
In addition, the clinical impression that patients with
more diffuse disease and those with proximal left anterior
descending disease (almost all of whom received internal
mammary artery grafts in the surgical group) may have
better outcomes with surgery was not established by this
study. There was a trend toward better survival with surgery
for the patients with proximal left anterior descending
coronary artery lesions (p 5 0.16).
Because of the structure of this trial, which required a
one- and three-year angiographic follow-up, the number of
repeat procedures was probably artificially elevated com-
pared with what it would have been without angiography.
Note the bumps on the procedure curves at 1 and 3 years
(Fig. 6 A–C). Comparison to the EAST registry, which did
not show this clustering of repeat procedures, confirms this
impression (13). These repeat procedures, influenced by
angiography, were almost equally present in both groups,
and it remains that repeat procedures are markedly excessive
in the angioplasty group. This effect was driven primarily by
restenosis after angioplasty producing the early divergence
of the curves within the first year (Fig. 6 A–C). It is
interesting to note that over the five years since the primary
study was completed, the percent of patients requiring a first
additional procedure actually favors angioplasty. This was
not unexpected since more surgical patients are eligible for
their first repeat procedure in the late follow-up.
The continuing occurrence of late events in both groups
speaks to the need to evaluate the impact of aggressive
secondary prevention measures in these revascularized pa-
tients. Such measures were not consistently applied in
EAST or the other angioplasty versus surgery trials. Two
studies, Clinical Outcome Utilizing Revascularization and
Aggressive Drug Evaluation (COURAGE) and BARI II,
which will utilize optimal risk modification, may improve
on the late results in such patients. Ongoing studies com-
paring angioplasty using stents to coronary bypass surgery
(Artery Revascularization Therapy Study and Stent or
Surgery) will likely significantly reduce the number of repeat
procedures in the angioplasty groups.
Study limitations. The study was not powered to detect a
difference in survival. It is possible that long-term follow-up
could show additional differences between the groups. Due
to the aging of the population (average age 70 at the
eight-year follow-up), about one half of the patients who
have died have had noncardiac causes of death, further
weakening the power to analyze cardiac survival differences.
Conclusions. This long-term follow-up of EAST contin-
ues to show no significant survival difference based on
treatment with surgery or angioplasty. Trends toward im-
proved survival with surgery in patients with diabetes and
proximal left anterior descending coronary disease should be
compared with other studies with adequate long-term
follow-up. Patients without treated diabetes have almost
identical survival at eight years. Whether the excess repeat
revascularization procedures and late vascular events can be
reduced with newer techniques such as stenting and sec-
ondary prevention awaits the outcome of subsequent trials,
which are underway.
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